Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells

References

• Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001; 84:417 - 22; http://dx.doi.org/10.1054/bjoc.2000.1582; PMID: 11161410
   PubMed Web of Science ®Google Scholar
• Verlato G, Zoppini G, Bonora E, Muggeo M. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 2003; 26:1047 - 51; http://dx.doi.org/10.2337/diacare.26.4.1047; PMID: 12663571
   PubMed Web of Science ®Google Scholar
• Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005; 2:48 - 53; http://dx.doi.org/10.1038/ncponc0062; PMID: 16264856
   PubMedGoogle Scholar
• Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159:1160 - 7; http://dx.doi.org/10.1093/aje/kwh161; PMID: 15191933
   PubMed Web of Science ®Google Scholar
• van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 2007; 120:1986 - 92; http://dx.doi.org/10.1002/ijc.22532; PMID: 17230509
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547 - 61; PMID: 10653870
   PubMed Web of Science ®Google Scholar
• Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004; 100:1179 - 85; http://dx.doi.org/10.1002/cncr.20071; PMID: 15022284
   PubMed Web of Science ®Google Scholar
• Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al, Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364:829 - 41; http://dx.doi.org/10.1056/NEJMoa1008862; PMID: 21366474
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science 1956; 123:309 - 14; http://dx.doi.org/10.1126/science.123.3191.309; PMID: 13298683
   PubMed Web of Science ®Google Scholar
• Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci 2008; 65:3981 - 99; http://dx.doi.org/10.1007/s00018-008-8224-x; PMID: 18766298
   PubMed Web of Science ®Google Scholar
• Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 2011; 15:825 - 36; http://dx.doi.org/10.1111/j.1582-4934.2010.01083.x; PMID: 20455996
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33:1674 - 85; http://dx.doi.org/10.2337/dc10-0666; PMID: 20587728
   PubMed Web of Science ®Google Scholar
• Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 2010; 70:2516 - 27; http://dx.doi.org/10.1158/0008-5472.CAN-09-3950; PMID: 20215516
   PubMed Web of Science ®Google Scholar
• Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007; 109:315 - 22; http://dx.doi.org/10.1182/blood-2006-04-013805; PMID: 16912224
   PubMed Web of Science ®Google Scholar
• Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009; 15:1686 - 97; http://dx.doi.org/10.1158/1078-0432.CCR-08-2141; PMID: 19240172
   PubMed Web of Science ®Google Scholar
• Malone JI, Lowitt S, Grove NP, Shah SC. Comparison of insulin levels after injection by jet stream and disposable insulin syringe. Diabetes Care 1986; 9:637 - 40; http://dx.doi.org/10.2337/diacare.9.6.637; PMID: 3542456
   PubMed Web of Science ®Google Scholar
• van Berlo-van de Laar IR, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011; 36:376 - 82; http://dx.doi.org/10.1111/j.1365-2710.2010.01192.x; PMID: 21545617
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003; 46:1319 - 23; http://dx.doi.org/10.1007/s00125-003-1181-x; PMID: 12898007
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804 - 12; http://dx.doi.org/10.1158/0008-5472.CAN-07-2310; PMID: 18006825
   PubMed Web of Science ®Google Scholar
• Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M, et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012; 26:91 - 100; http://dx.doi.org/10.1038/leu.2011.269; PMID: 21968881
   PubMed Web of Science ®Google Scholar
• Farrow B, Evers BM. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 2003; 301:50 - 3; http://dx.doi.org/10.1016/S0006-291X(02)02983-2; PMID: 12535639
   PubMed Web of Science ®Google Scholar
• Boren J, Cascante M, Marin S, Comín-Anduix B, Centelles JJ, Lim S, et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 2001; 276:37747 - 53; PMID: 11489902
   PubMed Web of Science ®Google Scholar
• Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 1974; 23:9 - 15; PMID: 4809622
   PubMed Web of Science ®Google Scholar
• Gapstur SM, Gann PH, Colangelo LA, Barron-Simpson R, Kopp P, Dyer A, et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control 2001; 12:763 - 72; http://dx.doi.org/10.1023/A:1011279907108; PMID: 11562117
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20:42 - 51; http://dx.doi.org/10.1200/JCO.20.1.42; PMID: 11773152
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003; 21:433 - 40; http://dx.doi.org/10.1200/JCO.2003.07.125; PMID: 12560431
   PubMed Web of Science ®Google Scholar
• Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 2011; 15:825 - 36; http://dx.doi.org/10.1111/j.1582-4934.2010.01083.x; PMID: 20477906
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52:1732 - 44; http://dx.doi.org/10.1007/s00125-009-1418-4; PMID: 19565214
   PubMed Web of Science ®Google Scholar
• Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52:1755 - 65; http://dx.doi.org/10.1007/s00125-009-1453-1; PMID: 19603149
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52:1766 - 77; http://dx.doi.org/10.1007/s00125-009-1440-6; PMID: 19572116
   PubMed Web of Science ®Google Scholar
• Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52:2499 - 506; http://dx.doi.org/10.1007/s00125-009-1530-5; PMID: 19756478
   PubMed Web of Science ®Google Scholar
• Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52:1745 - 54; http://dx.doi.org/10.1007/s00125-009-1444-2; PMID: 19588120
   PubMed Web of Science ®Google Scholar
• Wilson C. Diabetes: long-term use of insulin glargine might increase the risk of breast cancer. Nat Rev Endocrinol 2011; 7:499; http://dx.doi.org/10.1038/nrendo.2011.112; PMID: 21709708
   PubMedGoogle Scholar
• Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008; 114:38 - 44; http://dx.doi.org/10.1080/13813450801900645; PMID: 18465357
   PubMedGoogle Scholar
• Mayer D, Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 2010; 116:73 - 8; http://dx.doi.org/10.3109/13813451003631439; PMID: 20199195
   PubMedGoogle Scholar
• Liefvendahl E, Arnqvist HJ. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 2008; 40:369 - 74; http://dx.doi.org/10.1055/s-2008-1062739; PMID: 18393172
   PubMed Web of Science ®Google Scholar
• Erbel S, Reers C, Eckstein VW, Kleeff J, Büchler MW, Nawroth PP, et al. Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 2008; 31:1105 - 11; http://dx.doi.org/10.2337/dc07-2015; PMID: 18316392
   PubMed Web of Science ®Google Scholar
• Müller K, Weidinger C, Führer D. Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells. Diabetologia 2010; 53:1001 - 3; http://dx.doi.org/10.1007/s00125-010-1674-3; PMID: 20179899
   PubMed Web of Science ®Google Scholar
• Nagel JM, Staffa J, Renner-Müller I, Horst D, Vogeser M, Langkamp M, et al. Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Horm Cancer 2010; 1:320 - 30; http://dx.doi.org/10.1007/s12672-010-0020-z; PMID: 21761363
   PubMedGoogle Scholar
• Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896 - 917; PMID: 22203527
   PubMed Web of Science ®Google Scholar
• Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67:6745 - 52; http://dx.doi.org/10.1158/0008-5472.CAN-06-4447; PMID: 17638885
   PubMed Web of Science ®Google Scholar
• Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007; 64:1290 - 302; http://dx.doi.org/10.1007/s00018-007-7080-4; PMID: 17447005
   PubMed Web of Science ®Google Scholar
• Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 2008; 14:7192 - 8; http://dx.doi.org/10.3748/wjg.14.7192; PMID: 19084933
   PubMed Web of Science ®Google Scholar
• Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9:1091 - 6; http://dx.doi.org/10.4161/cc.9.6.11035; PMID: 20190568
   PubMed Web of Science ®Google Scholar
• Fenner MH, Elstner E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs 2005; 14:557 - 68; http://dx.doi.org/10.1517/13543784.14.6.557; PMID: 16004588
   PubMed Web of Science ®Google Scholar
• Lyles BE, Akinyeke TO, Moss PE, Stewart LV. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 2009; 8:268 - 77; http://dx.doi.org/10.4161/cc.8.2.7584; PMID: 19164938
   PubMed Web of Science ®Google Scholar
• Dong YW, Wang XP, Wu K. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J Gastroenterol 2009; 15:441 - 8; http://dx.doi.org/10.3748/wjg.15.441; PMID: 19152448
   PubMed Web of Science ®Google Scholar
• Papageorgiou E, Pitulis N, Manoussakis M, Lembessis P, Koutsilieris M. Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med 2008; 14:403 - 11; http://dx.doi.org/10.2119/2008-00021.Papageorgiou; PMID: 18475308
   PubMed Web of Science ®Google Scholar
• Cantini G, Lombardi A, Piscitelli E, Poli G, Ceni E, Marchiani S, et al. Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res 2008; 2008:904041; http://dx.doi.org/10.1155/2008/904041; PMID: 18670617
   PubMed Web of Science ®Google Scholar
• Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C. Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer 2006; 118:2390 - 8; http://dx.doi.org/10.1002/ijc.21799; PMID: 16425225
   PubMed Web of Science ®Google Scholar
• Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY) 2010; 2:760 - 74; PMID: 21084729
   PubMedGoogle Scholar
• Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010; 9:1781 - 91; http://dx.doi.org/10.4161/cc.9.9.11483; PMID: 20436278
   PubMed Web of Science ®Google Scholar
• Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7:455 - 65; http://dx.doi.org/10.1038/nrclinonc.2010.82; PMID: 20531380
   PubMed Web of Science ®Google Scholar
• He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2011; http://dx.doi.org/10.1093/annonc/mdr534; PMID: 22112968
   PubMed Web of Science ®Google Scholar
• He XX, Tu SM, Lee MH, Yeung SC. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011; 22:2640 - 5; http://dx.doi.org/10.1093/annonc/mdr020; PMID: 21415239
   PubMed Web of Science ®Google Scholar
• Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012; 18:2905 - 12; http://dx.doi.org/10.1158/1078-0432.CCR-11-2994; PMID: 22465831
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29:254 - 8; http://dx.doi.org/10.2337/diacare.29.02.06.dc05-1558; PMID: 16443869
   PubMed Web of Science ®Google Scholar
• Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27:3297 - 302; http://dx.doi.org/10.1200/JCO.2009.19.6410; PMID: 19487376
   PubMed Web of Science ®Google Scholar
• Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, et al. A randomized controlled trial of an intensive insulin regimen in hyperglycemic acute lymphoblastic leukemia patients. Clin Lymphoma Myeloma Leuk 2012; In press
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011; 126:215 - 20; http://dx.doi.org/10.1007/s10549-010-1224-1; PMID: 20976543
   PubMed Web of Science ®Google Scholar
• Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222 - 33; PMID: 21447859
   PubMed Web of Science ®Google Scholar
• Jin Y, Chen Q, Shi X, Lu Z, Cheng C, Lai Y, et al. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci 2009; 100:1335 - 43; http://dx.doi.org/10.1111/j.1349-7006.2009.01159.x; PMID: 19383029
   PubMed Web of Science ®Google Scholar